Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    181 - 190 out of 235Page size: 10
    1. 2005
    2. Published

      Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

      Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      MK-431 (Merck).

      Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      What do we know about the secretion and degradation of incretin hormones?

      Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.

      Gram, D. X., Hansen, A. J., Deacon, Carolyn F., Brand, C. L., Ribel, U., Wilken, M., Carr, R. D., Svendsen, O. & Ahrén, B., 2005, In: European Journal of Pharmacology. 509, 2-3, p. 211-7 6 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      For debate: Are antidiabetic actions of DPP-IV inhibitors mediated by glucagon-like peptide- 1?

      Holst, Jens Juul & Deacon, Carolyn F., 2005, In: Diabetologia. 48, p. 612-615

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

      Holst, Jens Juul & Deacon, Carolyn F., Apr 2005, In: Diabetologia. 48, 4, p. 612-5 4 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      Glucagon-like peptide-1 mediates the therapeutic actions of Dpp-IV inhibitors

      Holst, Jens Juul & Deacon, Carolyn F., 2005, In: Diabetologia. 48, p. 612-615

      Research output: Contribution to journal › Journal article › Research › peer-review

    9. Published

      Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

      Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, Carolyn F., Holst, Jens Juul & Foley, J. E., Aug 2005, In: The Journal of clinical endocrinology and metabolism. 90, 8, p. 4888-94 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Published

      The incretin enhancer vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed -cell function in patients with type 2 diabetes

      Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, Carolyn F., Holst, Jens Juul & Foley, J. E., 2005, In: Journal of Clinical Endocrinology and Metabolism. 90, p. 4888-4894

      Research output: Contribution to journal › Journal article › Research

    11. Published

      Vildagliptin, a dipeptidyl peptidase-IV inhibitor improves model-assessed beta-cell function in patients with type 2 diabetes

      Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Duning, B. E., Deacon, Carolyn F., Holst, Jens Juul & Foley, J. E., 2005, In: J. Clin. Endocrinol. Metab.. 90, p. 4888-4894

      Research output: Contribution to journal › Journal article › Research

    Previous 1...15 16 17 18 19 20 21 22 ...24 Next

    ID: 9220